Unjoni Ewropea - Malti - EMA (European Medicines Agency)

ceva santé animale - inactivated fimbrial adhesins of escherichia coli f4ab, inactivated fimbrial adhesins of escherichia coli f4ac, inactivated fimbrial adhesins of escherichia coli f5, inactivated fimbrial adhesins of escherichia coli f6 - immunoloġiċi għal suidae - majjali - for the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce clinical signs (severe diarrhoea) and mortality caused by escherichia coli strains expressing the fimbrial adhesins f4ab, f4ac, f5 and f6.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

zoetis belgium sa - wieħed minn dawn li ġejjin inattivat tal-virus tal-bluetongue razez:inattivat tal-virus tal-bluetongue serotip 1, tar-razza btv-1/alg2006/01 e1inactivated-virus tal-bluetongue serotip 8, razza btv-8/bel2006/02inactivated-virus tal-bluetongue serotip 4, razza spa-1/2004 - immunoloġiċi, immunoloġiċi għall-bovini, vaċċini virali inattivati, virus tal-bluetongue, nagĦaĠ - sheep; cattle - immunizzazzjoni attiva ta 'nagħaġ mill-età ta' 6 ġimgħat għall-prevenzjoni tal-viremija kkawżata mill-virus tal-bluetongue, is-serotipi 1 u 8, u għat-tnaqqis tal-viremija kkawżata mill-virus tal-bluetongue serotip 4 u t-tilqim attiv ta 'baqar minn 12-il ġimgħa ta' l-età għall-prevenzjoni tal-viremija kkawżata mill-virus tal-bluetongue, is-serotipi 1 u 8.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - hepatitis a virus (inactivated), hepatitis b surface antigen - hepatitis b; hepatitis a; immunization - vaċċini - ambirix huwa għall-użu f'persuni mhux immuni minn sena sa u li jinkludu 15-il sena għall-protezzjoni kontra l-infezzjoni tal-epatite-a u l-epatite-b. il-protezzjoni kontra l-epatite b infezzjonijiet tista'ma tinkisibx sa wara t-tieni doża. għalhekk:ambirix għandu jintuża biss meta jkun hemm riskju relattivament żgħir ta 'l-epatite b infezzjoni matul il-kors ta' tilqim;huwa rakkomandat li ambirix jingħata f'sitwazzjonijiet meta t-tlestija ta 'l-żewġ dożi tal-kors tal-vaċċinazzjoni tista' tkun assigurata.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

cz veterinaria s.a. - bluetongue virus vaccine serotypes 1 or 4 or 8 [inactivated] - immunoloġiċi - sheep; cattle - sheepactive-tilqim kontra l-virus tal-bluetongue tas-serotip 8 għall-prevenzjoni kontra viremja u biex tnaqqas sinjali kliniċi. il-bidu tal-immunità: 20 jum wara t-tieni doża. tul ta 'żmien tal-immunità: sena wara t-tieni doża. cattleactive-tilqim kontra l-virus tal-bluetongue tas-serotip 8 għall-prevenzjoni kontra viremja. il-bidu tal-immunità: 31 jum wara t-tieni doża. tul ta 'żmien tal-immunità: sena wara t-tieni doża.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

laboratorios hipra s.a. - escherichia coli j5 inactivated, staphylococcus aureus (cp8) strain sp 140 inactivated, expressing slime-associated antigenic complex - immunoloġiċi għall-bovidae - baqar (baqar u erħiet) - għat-tilqim tal-merħla ta 'baqar u erieħ, fil-ħalib tal-merħliet tal-baqar bil-mastite rikorrenti problemi, biex titnaqqas l-inċidenza tal-sub-mastite klinika u l-inċidenza u s-severità tas-sinjali kliniċi ta' mastite klinika kkawżata minn staphylococcus aureus, koliformi u coagulase-negative staphylococci. l-iskema sħiħa tat-tilqim twassal għall-immunità minn bejn wieħed u ieħor jum 13 wara l-ewwel injezzjoni sa bejn wieħed u ieħor 78 jum wara t-tielet injezzjoni (ekwivalenti għal 130 jum wara t-twelid).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - hepatitis a virus (inactivated), hepatitis b surface antigen - immunization; hepatitis b; hepatitis a - vaċċini - twinrix pediatric huwa indikat għall-użu fi trabi mhux immuni, tfal u adolexxenti minn sena sa u li jinkludu 15-il sena li huma f'riskju kemm ta 'infezzjoni ta' l-epatite-a kif ukoll ta 'l-epatite-b.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

ceva santé animale - influenza a virus/human strain: a/jena/vi5258/2009 (h1n1)pdm09, inactivated - immunoloġiċi, vaċċini virali inattivati għall-ħnieżer, porċini-virus tal-influwenza - majjali - immunizzazzjoni attiva ta 'majjali mill-età ta' 8 ġimgħat 'il quddiem kontra l-virus pandemiku h1n1 tal-influwenza tal-ħnieżer biex tnaqqas it-tagħbija tal-pulmun virali u l-eskrezzjoni virali. the vaccine can be used during pregnancy up to three weeks before expected farrowing and during lactation lactation.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - immunoloġiċi għal suidae - Ħnieżer (għall-tismin) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d. active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection.  onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination.  duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination.  in addition, vaccination has been shown to reduce body weight gain losses under field conditions.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

seqirus s.r.l.  - zoonotic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted), influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza a virus, h5n1 subtype - vaċċini - active immunisation against h5 subtype of influenza a virus.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

ceva santé animale - vaċċin inattivat ta 'coxiella burnetii, strain nine mile - immunologicals for bovidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - goats; cattle - cattle: , for the active immunisation of cattle to lower the risk for non-infected animals vaccinated when non-pregnant to become shedder (5 times lower probability in comparison with animals receiving a placebo), and to reduce shedding of coxiella burnetii in these animals via milk and vaginal mucus. , onset of immunity: not established. , duration of immunity: 280 days after completion of the primary vaccination course. , goats: , for the active immunisation of goats to reduce abortion caused by coxiella burnetii and to reduce shedding of the organism via milk, vaginal mucus, faeces and placenta. , onset of immunity: not established. , duration of immunity: one year after completion of the primary vaccination course.